Abstract:Levodopa (L-DOPA) is the most effective drug for Parkinson's disease; however, various side effects occur during therapy. L-DOPA metabolites and the high cumulative dose of L-DOPA were responsible for its side effects. It is necessary to monitor the concentration of L-DOPA and its metabolites for individualized therapy. This review focuses on L-DOPA analysis by chromatography-based methods in biological matrices. Literature published up to September 2021 was collected in the PubMed, Web of Science, and Embase by using search strategy ("levodopa" OR "L-DOPA") AND ("chromatography"). A total of 1249 articles were identified and 32 articles were included. The contents for method development and validation were summarized and analyzed. Due to the instability of catecholamines (L-DOPA, dopamine, and 3-O-methyldopa) and carbidopa, antioxidation (0.5 mg sodium metabisulfite for 100 μL sample) and environment temperature control were used alone or in combination to enhance stability. Sample was mainly pretreated by protein precipitation (0.4-0.7 M perchloric acid). Separation was usually achieved using methanol or acetonitrile:water (with formic acid) on C18 columns. Mass spectrometry, electrochemical detector, ultraviolet-visible detector and fluorescence detector were used for detection. For L-DOPA, the calibration range was 2.5-10,000 ng/mL, the matrix effect and its coefficient of variation was 85-115 and -9.0-8.5%, and the recovery was 66.8-127.0%. Without stabilization strategy, L-DOPA was stable in plasma at room temperature for 1-7 h (4-6 h for most studies), at - 70 °C to - 80 °C for 10-20 days and after 3-5 freeze-thaw cycles. With stabilization strategies, the stability of L-DOPA in plasma was significantly improved. Metabolites of L-DOPA and enzyme inhibitors (carbidopa, entacapone, tolcapone and benserazide) were all stable in biological matrix. This study might be useful for researchers to develop their methods for individualized therapy of patients with Parkinson.

Blue and Green Emission-Transformed Fluorescent Copolymer: Specific Detection of Levodopa of Anti-Parkinson Drug in Human Serum

Differential Coulometry Based on Dual Screen-Printed Strips for High Accuracy Levodopa Determination Towards Parkinson's Disease Management

Differential Amperometric Microneedle Biosensor for Wearable Levodopa Monitoring of Parkinson's Disease

Minimal-Invasive Levodopa Sensing Based on Differential Amperometry Microneedle Electrodes Decorated with Spike-like Au Nanoparticles

Simultaneous sensing of carbidopa and levodopa by a novel strategy based on dual‐emission ratiometric assay of modified carbon dots

Glutathione-decorated fluorescent carbon quantum dots for sensitive and selective detection of levodopa

Simultaneous Determination of Levodopa and Its Metabolite in Human Blood by Capillary Electrophoresis with Laser‐induced Fluorescence Detection

Determination of Levodopa in Both Human Urine and Plasma Samples Using Excitation-emission Matrix Fluorescence Coupled with Second-order Calibration

Microdialysis Sampling and High-Performance Liquid Chromatography with Chemiluminescence Detection for In-Vivo On-Line Determination and Study of the Pharmacokinetics of Levodopa in Blood

A bacterial cellulose-based LiSrVO4:Eu3+ nanosensor platform for smartphone sensing of levodopa and dopamine: point-of-care diagnosis of Parkinson's disease

Label-Free and Highly Selective Mofs-Based Dopamine Detection in Urine of Parkinson's Patients

Determination of levodopa by chromatography-based methods in biological samples: a review

Flexible Electrochemical Sensor for Simultaneous Determination of Levodopa and Uric Acid Based on Carbon Nanotube Fibers

Polyvinylpyrrolidone‐Stabilized Blue‐Emitting Copper Nanoclusters as Fluorescence Probe for Selective Detection of Dopamine

Electrocatalytic Oxidation of Levodopa at A Ferrocene Modified Carbon Nanotube Paste Electrode

Facile and Sensitive Detection of Dopamine Based on in Situ Formation of Fluorescent Polydopamine Nanoparticles Catalyzed by Peroxidase-Like Ficin

Label-free and highly selective MOFs-based dopamine detection in urine of Parkinson’s patients

A fluorescence probe based on carbon dots for determination of dopamine utilizing its self-polymerization

Review of the Analytical Methods for Levodopa

Chiral FexCuySe Nanoparticles As Peroxidase Mimics for Colorimetric Detection of 3, 4-Dihydroxy-phenylalanine Enantiomers.

Spectral resolution techniques for the simultaneous spectrophotometric determination of anti-Parkinson drugs in their combined pharmaceutical dosage form and biological sample based on multivariate calibration and absorbance subtraction methods